Company intelligence / Profile preview
CHX Technologies
- Ownership
- Private
- Employees
- ~2
- Development stage
- Commercial
Overview
Prevora, the company’s lead product, is a clear topical antibacterial tooth coating approved for preventing dental decay and gum disease in high-risk adults. It has completed Phase III studies and is approved for use in Canada and Europe. Clinical results show it is painless, safe, effective at reducing oral dysbiosis and improving oral health outcomes over years of use. Studies are ongoing to expand its integration into medical practices and home care settings.
- Therapeutic areas
- ImmunologyInfectious Diseases
- Modalities
- Small moleculeAntiseptic (topical antibacterial)
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on CHX Technologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHX Technologies.